| Literature DB >> 31988457 |
David B Chou1,2, Viktoras Frismantas1, Yuka Milton1, Rhiannon David3, Petar Pop-Damkov4, Douglas Ferguson4, Alexander MacDonald5, Özge Vargel Bölükbaşı6, Cailin E Joyce7,8, Liliana S Moreira Teixeira1, Arianna Rech1,9, Amanda Jiang10, Elizabeth Calamari1, Sasan Jalili-Firoozinezhad1,11, Brooke A Furlong1, Lucy R O'Sullivan1, Carlos F Ng1, Youngjae Choe1, Susan Marquez1, Kasiani C Myers12,13, Olga K Weinberg14, Robert P Hasserjian2, Richard Novak1, Oren Levy1, Rachelle Prantil-Baun1, Carl D Novina7,8,15, Akiko Shimamura6, Lorna Ewart3, Donald E Ingber16,17,18.
Abstract
The inaccessibility of living bone marrow (BM) hampers the study of its pathophysiology under myelotoxic stress induced by drugs, radiation or genetic mutations. Here, we show that a vascularized human BM-on-a-chip (BM chip) supports the differentiation and maturation of multiple blood cell lineages over 4 weeks while improving CD34+ cell maintenance, and that it recapitulates aspects of BM injury, including myeloerythroid toxicity after clinically relevant exposures to chemotherapeutic drugs and ionizing radiation, as well as BM recovery after drug-induced myelosuppression. The chip comprises a fluidic channel filled with a fibrin gel in which CD34+ cells and BM-derived stromal cells are co-cultured, a parallel channel lined by human vascular endothelium and perfused with culture medium, and a porous membrane separating the two channels. We also show that BM chips containing cells from patients with the rare genetic disorder Shwachman-Diamond syndrome reproduced key haematopoietic defects and led to the discovery of a neutrophil maturation abnormality. As an in vitro model of haematopoietic dysfunction, the BM chip may serve as a human-specific alternative to animal testing for the study of BM pathophysiology.Entities:
Mesh:
Substances:
Year: 2020 PMID: 31988457 PMCID: PMC7160021 DOI: 10.1038/s41551-019-0495-z
Source DB: PubMed Journal: Nat Biomed Eng ISSN: 2157-846X Impact factor: 25.671